|
Thyroid Gland Papillary Carcinoma
Thyroid Gland Papillary Carcinoma
|
trametinib + dabrafenib + AZD1775
Sensitive: D – Preclinical
Cancers (Basel) - 3 weeks
|
WEE1 underexpression
WEE1 underexpression
|
Thyroid Gland Carcinoma
Thyroid Gland Carcinoma
|
AZD1775
Sensitive: D – Preclinical
Cancers (Basel) - 3 weeks
|
No biomarker
No biomarker
|
Thyroid Gland Medullary Carcinoma
Thyroid Gland Medullary Carcinoma
|
|
|
Thyroid Gland Carcinoma
Thyroid Gland Carcinoma
|
|
RET mutation
RET mutation
|
Thyroid Gland Medullary Carcinoma
Thyroid Gland Medullary Carcinoma
|
|
|
Thyroid Gland Carcinoma
Thyroid Gland Carcinoma
|
|
No biomarker
No biomarker
|
Thyroid Gland Hurthle Cell Carcinoma
Thyroid Gland Hurthle Cell Carcinoma
|
|
No biomarker
No biomarker
|
Thyroid Gland Follicular Carcinoma
Thyroid Gland Follicular Carcinoma
|
|
No biomarker
No biomarker
|
Thyroid Gland Papillary Carcinoma
Thyroid Gland Papillary Carcinoma
|
|
No biomarker
No biomarker
|
Thyroid Gland Follicular Carcinoma
Thyroid Gland Follicular Carcinoma
|
|
No biomarker
No biomarker
|
Thyroid Gland Hurthle Cell Carcinoma
Thyroid Gland Hurthle Cell Carcinoma
|
|
No biomarker
No biomarker
|
Thyroid Gland Papillary Carcinoma
Thyroid Gland Papillary Carcinoma
|
|
No biomarker
No biomarker
|
Thyroid Gland Medullary Carcinoma
Thyroid Gland Medullary Carcinoma
|
|
|
Thyroid Gland Anaplastic Carcinoma
Thyroid Gland Anaplastic Carcinoma
|
|
RET mutation
RET mutation
|
Thyroid Gland Medullary Carcinoma
Thyroid Gland Medullary Carcinoma
|
|
|
Thyroid Gland Anaplastic Carcinoma
Thyroid Gland Anaplastic Carcinoma
|
|
No biomarker
No biomarker
|
Thyroid Gland Carcinoma
Thyroid Gland Carcinoma
|
|
No biomarker
No biomarker
|
Head and Neck Cancer
Head and Neck Cancer
|
|
No biomarker
No biomarker
|
Nasopharyngeal Carcinoma
Nasopharyngeal Carcinoma
|
|
NTRK1 fusion
NTRK1 fusion
|
Thyroid Gland Follicular Carcinoma
Thyroid Gland Follicular Carcinoma
|
entrectinib
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Thyroid Gland Medullary Carcinoma
Thyroid Gland Medullary Carcinoma
|
dacarbazine
Sensitive: A2 - Guideline
|
NTRK2 fusion
NTRK2 fusion
|
Thyroid Gland Follicular Carcinoma
Thyroid Gland Follicular Carcinoma
|
entrectinib
Sensitive: A2 - Guideline
|
NTRK3 fusion
NTRK3 fusion
|
Thyroid Gland Follicular Carcinoma
Thyroid Gland Follicular Carcinoma
|
entrectinib
Sensitive: A2 - Guideline
|
NTRK1 fusion
NTRK1 fusion
|
Thyroid Gland Hurthle Cell Carcinoma
Thyroid Gland Hurthle Cell Carcinoma
|
entrectinib
Sensitive: A2 - Guideline
|
NTRK2 fusion
NTRK2 fusion
|
Thyroid Gland Hurthle Cell Carcinoma
Thyroid Gland Hurthle Cell Carcinoma
|
entrectinib
Sensitive: A2 - Guideline
|
NTRK1 fusion
NTRK1 fusion
|
Thyroid Gland Follicular Carcinoma
Thyroid Gland Follicular Carcinoma
|
larotrectinib
Sensitive: A2 - Guideline
|
NTRK2 fusion
NTRK2 fusion
|
Thyroid Gland Follicular Carcinoma
Thyroid Gland Follicular Carcinoma
|
larotrectinib
Sensitive: A2 - Guideline
|
NTRK3 fusion
NTRK3 fusion
|
Thyroid Gland Follicular Carcinoma
Thyroid Gland Follicular Carcinoma
|
larotrectinib
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Oropharyngeal Cancer
Oropharyngeal Cancer
|
TPF
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
|
pembrolizumab
Sensitive: A2 - Guideline
|
PD-L1 expression
PD-L1 expression
|
|
pembrolizumab
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
|
cisplatin + paclitaxel + 5-fluorouracil
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
|
paclitaxel
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
|
nivolumab
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
|
methotrexate
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
|
docetaxel
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
|
cisplatin + docetaxel
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
|
carboplatin + paclitaxel
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
|
cetuximab
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
|
capecitabine
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
|
afatinib
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
|
5-fluorouracil
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
|
cisplatin
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
|
cisplatin + 5-fluorouracil + docetaxel
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
|
cisplatin + paclitaxel
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Oropharyngeal Cancer
Oropharyngeal Cancer
|
cisplatin + paclitaxel
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Oropharyngeal Cancer
Oropharyngeal Cancer
|
afatinib
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Oropharyngeal Cancer
Oropharyngeal Cancer
|
capecitabine
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Oropharyngeal Cancer
Oropharyngeal Cancer
|
methotrexate
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Oropharyngeal Cancer
Oropharyngeal Cancer
|
5-fluorouracil
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Oropharyngeal Cancer
Oropharyngeal Cancer
|
docetaxel
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Oropharyngeal Cancer
Oropharyngeal Cancer
|
paclitaxel
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Oropharyngeal Cancer
Oropharyngeal Cancer
|
carboplatin
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Oropharyngeal Cancer
Oropharyngeal Cancer
|
pembrolizumab
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Oropharyngeal Cancer
Oropharyngeal Cancer
|
cetuximab
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Oropharyngeal Cancer
Oropharyngeal Cancer
|
carboplatin + paclitaxel
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Oropharyngeal Cancer
Oropharyngeal Cancer
|
cisplatin + docetaxel
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Oropharyngeal Cancer
Oropharyngeal Cancer
|
nivolumab
Sensitive: A2 - Guideline
|
PD-L1 expression
PD-L1 expression
|
Oropharyngeal Cancer
Oropharyngeal Cancer
|
pembrolizumab
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Oropharyngeal Cancer
Oropharyngeal Cancer
|
cisplatin + paclitaxel + 5-fluorouracil
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
|
cisplatin + 5-fluorouracil
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
|
5-fluorouracil + hydroxyurea
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
|
carboplatin + 5-fluorouracil
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Oropharyngeal Cancer
Oropharyngeal Cancer
|
cisplatin + 5-fluorouracil
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Oropharyngeal Cancer
Oropharyngeal Cancer
|
5-fluorouracil + hydroxyurea
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Oropharyngeal Cancer
Oropharyngeal Cancer
|
carboplatin + 5-fluorouracil
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Oropharyngeal Cancer
Oropharyngeal Cancer
|
cisplatin
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Nasopharyngeal Carcinoma
Nasopharyngeal Carcinoma
|
GC
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Nasopharyngeal Carcinoma
Nasopharyngeal Carcinoma
|
carboplatin + paclitaxel
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Maxillary Sinus Carcinoma
Maxillary Sinus Carcinoma
|
VC
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Maxillary Sinus Carcinoma
Maxillary Sinus Carcinoma
|
EP
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Maxillary Sinus Carcinoma
Maxillary Sinus Carcinoma
|
CAV
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Nasopharyngeal Carcinoma
Nasopharyngeal Carcinoma
|
DP
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Nasopharyngeal Carcinoma
Nasopharyngeal Carcinoma
|
TPF
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Thyroid Gland Anaplastic Carcinoma
Thyroid Gland Anaplastic Carcinoma
|
CaT
Sensitive: A2 - Guideline
|
|
Maxillary Sinus Carcinoma
Maxillary Sinus Carcinoma
|
pembrolizumab
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Nasopharyngeal Carcinoma
Nasopharyngeal Carcinoma
|
cetuximab
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Nasopharyngeal Carcinoma
Nasopharyngeal Carcinoma
|
oxaliplatin
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Nasopharyngeal Carcinoma
Nasopharyngeal Carcinoma
|
doxorubicin hydrochloride
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Nasopharyngeal Carcinoma
Nasopharyngeal Carcinoma
|
ifosfamide
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Nasopharyngeal Carcinoma
Nasopharyngeal Carcinoma
|
vinorelbine tartrate
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Nasopharyngeal Carcinoma
Nasopharyngeal Carcinoma
|
irinotecan
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Nasopharyngeal Carcinoma
Nasopharyngeal Carcinoma
|
capecitabine
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Nasopharyngeal Carcinoma
Nasopharyngeal Carcinoma
|
5-fluorouracil
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Nasopharyngeal Carcinoma
Nasopharyngeal Carcinoma
|
docetaxel
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Nasopharyngeal Carcinoma
Nasopharyngeal Carcinoma
|
paclitaxel
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Nasopharyngeal Carcinoma
Nasopharyngeal Carcinoma
|
nedaplatin
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Nasopharyngeal Carcinoma
Nasopharyngeal Carcinoma
|
cisplatin
Sensitive: A2 - Guideline
|
NTRK2 fusion
NTRK2 fusion
|
Thyroid Gland Papillary Carcinoma
Thyroid Gland Papillary Carcinoma
|
larotrectinib
Sensitive: A2 - Guideline
|
|
Thyroid Gland Hurthle Cell Carcinoma
Thyroid Gland Hurthle Cell Carcinoma
|
pembrolizumab
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Thyroid Gland Hurthle Cell Carcinoma
Thyroid Gland Hurthle Cell Carcinoma
|
denosumab
Sensitive: A2 - Guideline
|
HER-2 positive
HER-2 positive
|
Salivary Gland Cancer
Salivary Gland Cancer
|
trastuzumab
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Thyroid Gland Follicular Carcinoma
Thyroid Gland Follicular Carcinoma
|
denosumab
Sensitive: A2 - Guideline
|
|
Thyroid Gland Follicular Carcinoma
Thyroid Gland Follicular Carcinoma
|
pembrolizumab
Sensitive: A2 - Guideline
|
